Seth Klarman's hedge fund firm Baupost Group has increased its stake in Idenix Pharmaceuticals (IDIX) per an amended 13D and Form 4 filed with the SEC.
Per the filings, Baupost has disclosed a 35.38% ownership stake in IDIX with over 53.3 million shares. This means they've added to their position size by more than 16.4 million shares since November when they also added to their Idenix stake.
The Form 4 details that Baupost acquired those shares at a price of $6.5 on January 31st. This was part of a registered direct offering from the company that Baupost took part in. They are the company's largest shareholder.
Per Google Finance, Idenix Pharmaceuticals is "a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France."
You can view other recent portfolio activity from Baupost here.
Wednesday, February 5, 2014
Baupost Group Increases Idenix Pharmaceuticals Stake
blog comments powered by Disqus
